PRTA
Price
$11.94
Change
-$2.10 (-14.96%)
Updated
Dec 18, 04:59 PM (EDT)
56 days until earnings call
RGNX
Price
$7.77
Change
-$0.70 (-8.26%)
Updated
Dec 18, 04:59 PM (EDT)
75 days until earnings call
Ad is loading...

PRTA vs RGNX

Header iconPRTA vs RGNX Comparison
Open Charts PRTA vs RGNXBanner chart's image
Prothena
Price$11.94
Change-$2.10 (-14.96%)
Volume$3.06K
CapitalizationN/A
REGENXBIO
Price$7.77
Change-$0.70 (-8.26%)
Volume$12.88K
CapitalizationN/A
PRTA vs RGNX Comparison Chart
Loading...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRTA vs. RGNX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRTA is a Buy and RGNX is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (PRTA: $11.95 vs. RGNX: $7.77)
Brand notoriety: PRTA and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRTA: 176% vs. RGNX: 140%
Market capitalization -- PRTA: $643.01M vs. RGNX: $384.97M
PRTA [@Biotechnology] is valued at $643.01M. RGNX’s [@Biotechnology] market capitalization is $384.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRTA’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • PRTA’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than PRTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRTA’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • PRTA’s TA Score: 5 bullish, 3 bearish.
  • RGNX’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, PRTA is a better buy in the short-term than RGNX.

Price Growth

PRTA (@Biotechnology) experienced а -15.55% price change this week, while RGNX (@Biotechnology) price change was -16.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

PRTA is expected to report earnings on Feb 13, 2025.

RGNX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRTA($643M) has a higher market cap than RGNX($385M). RGNX YTD gains are higher at: -56.713 vs. PRTA (-67.116). PRTA has higher annual earnings (EBITDA): -167.23M vs. RGNX (-217.82M). PRTA has more cash in the bank: 519M vs. RGNX (255M). PRTA has less debt than RGNX: PRTA (11.5M) vs RGNX (84.1M). PRTA has higher revenues than RGNX: PRTA (133M) vs RGNX (84.3M).
PRTARGNXPRTA / RGNX
Capitalization643M385M167%
EBITDA-167.23M-217.82M77%
Gain YTD-67.116-56.713118%
P/E RatioN/AN/A-
Revenue133M84.3M158%
Total Cash519M255M204%
Total Debt11.5M84.1M14%
FUNDAMENTALS RATINGS
PRTA vs RGNX: Fundamental Ratings
PRTA
RGNX
OUTLOOK RATING
1..100
7459
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
9089
P/E GROWTH RATING
1..100
9527
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRTA's Valuation (60) in the Biotechnology industry is in the same range as RGNX (74). This means that PRTA’s stock grew similarly to RGNX’s over the last 12 months.

PRTA's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as RGNX (100). This means that PRTA’s stock grew similarly to RGNX’s over the last 12 months.

PRTA's SMR Rating (94) in the Biotechnology industry is in the same range as RGNX (98). This means that PRTA’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (89) in the Biotechnology industry is in the same range as PRTA (90). This means that RGNX’s stock grew similarly to PRTA’s over the last 12 months.

RGNX's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for PRTA (95). This means that RGNX’s stock grew significantly faster than PRTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRTARGNX
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
76%
Bullish Trend 11 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MECZX47.91N/A
N/A
AMG GW&K International Small Cap Z
JDEUX44.82N/A
N/A
JPMorgan US Research Enhanced Equity R6
PMIRX10.82-0.01
-0.09%
Putnam Multi-Asset Income R
SOPVX52.04-0.58
-1.10%
Allspring Opportunity A
AREDX26.09-1.09
-4.01%
American Century Real Estate R6

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with PEPG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then PEPG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
-14.89%
PEPG - PRTA
53%
Loosely correlated
-5.58%
DNLI - PRTA
51%
Loosely correlated
-7.71%
BEAM - PRTA
50%
Loosely correlated
-7.45%
NAUT - PRTA
47%
Loosely correlated
-8.59%
RGNX - PRTA
46%
Loosely correlated
-8.26%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-8.26%
BEAM - RGNX
49%
Loosely correlated
-7.45%
DNLI - RGNX
49%
Loosely correlated
-7.71%
AXON - RGNX
48%
Loosely correlated
-4.06%
PRTA - RGNX
45%
Loosely correlated
-14.89%
CRSP - RGNX
45%
Loosely correlated
-8.00%
More